null

Platelet aggregation inhibition" refers to the therapeutic prevention or reduction of platelet clumping (aggregation), a crucial step in the formation of blood clots (thrombi). Drugs or compounds that inhibit platelet aggregation target various molecules essential for platelet activation and adhesion, such as cyclooxygenase-1 (COX-1), ADP receptor (P2Y12), glycoprotein IIb/IIIa receptor, thrombin receptor PAR-1, and prostacyclin or nitric oxide signaling pathways. Platelet aggregation inhibitors are key agents in the prevention and treatment of cardiovascular diseases including myocardial infarction, stroke, and atherosclerosis, but their use poses increased risk of bleeding and other safety concerns. The process of platelet aggregation is complex and involves multiple receptors and signaling molecules, so "platelet aggregation inhibition" is not a specific molecular target, but rather describes the outcome of modulating these targets with drugs or biologically active compounds.

Other names

Platelet aggregation inhibitorAntiplatelet effectPlatelet inhibition

Cyclooxygenase-1 (COX-1) inhibition (e.g., aspirin) reduces thromboxane A2 formation. P2Y12 ADP receptor antagonism (e.g., clopidogrel, prasugrel, ticagrelor, cangrelor) prevents ADP-mediated platelet activation. Glycoprotein IIb/IIIa receptor antagonism (eptifibatide, tirofiban, abciximab) blocks fibrinogen binding and platelet aggregation. Thrombin receptor (PAR-1) antagonism (vorapaxar) inhibits thrombin-induced platelet activation. Phosphodiesterase inhibition (dipyridamole, cilostazol) increases cAMP/cGMP, reducing platelet reactivity. Prostacyclin receptor (IP) agonists (iloprost, selexipag, treprostinil) elevate cAMP, inhibiting platelet aggregation. Glycoprotein VI/collagen receptor antagonism (experimental/novel compounds). GPIb-von Willebrand factor axis antagonism (experimental/novel compounds)